We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Josee Rose
AstraZeneca PLC (AZN) on Tuesday said the U.S. Food and Drug Administration has accepted a supplemental biologics license application for Imfinzi, granting the drug Priority Review status.
Imfinzi is being developed to treat patients with stage 3 unresectable non-small cell lung cancer whose disease hasn't progressed after some chemoradiation therapy.
Imfinzi has had positive data from a phase 3 trial, which continues to evaluate overall survival, one of its primary endpoints.
Write to Josee Rose at josee.rose@wsj.com.
(END) Dow Jones Newswires
October 17, 2017 02:46 ET (06:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
